Establishment Labs (ESTA) raised its 2026 revenue guidance and narrowed operating losses, signaling accelerating adoption of its Cellfina cellulite-treatment platform and body-contouring device portfolio. The guidance lift reflects both domestic U.S. traction and international expansion, particularly in markets where cellulite treatment commands premium pricing and high patient satisfaction.
Business & M&A
Establishment Labs Raises 2026 Revenue Guidance
ESTA narrows losses and lifts outlook on Cellfina and body-contouring traction.
1-YEAR MOVE
ESTA
▲88.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ESTA | Establishment Labs | +88.6% |
Cellfina and body-contouring traction narrows losses, lifts 2026 guidance.
Cellfina's mechanism—subcision via a proprietary cannula to release fibrous septae—occupies a clinical niche that injectables and energy devices cannot address, which supports pricing power and repeat-patient economics. For practices considering Cellfina acquisition or partnership, ESTA's improving profitability suggests the company is moving toward sustainable unit economics, reducing the risk of discontinued support or pricing volatility. The narrowing losses also indicate that ESTA is approaching breakeven, which typically precedes margin expansion and reinvestment in clinical evidence and sales infrastructure.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.